Inhibition of prostate-specific membrane antigen (PSMA)-positive tumor growth by vaccination with either full-length or the C-terminal end of PSMA

International Journal of Cancer

Volumn 102, Issue 3, 2002, Pages 244-249

  Kuratsukuri, Katsuyuki ^a,b   Sone, Tomomichi ^c   Wang, Ching Y ^a,b   Nishisaka, Nobuyasu ^a,b   Jones, Richard F ^a,b   Haas, Gabriel P ^a,b  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b SYRACUSE VA MEDICAL CENTER   (United States)

^c SETSUNAN UNIVERSITY   (Japan)

Author keywords

Immunotherapy; Prostate cancer; Prostate specific membrane antigen

Indexed keywords

PROSTATE SPECIFIC MEMBRANE ANTIGEN; TRANSFERRIN RECEPTOR;

AMINO ACID SEQUENCE; ANIMAL CELL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNOCYTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; TUMOR XENOGRAFT; VACCINATION;

3T3 CELLS; ANIMALS; ANTIGENS, SURFACE; CANCER VACCINES; CARBOXYPEPTIDASES; CELL SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENETIC VECTORS; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0037145729     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10700     Document Type: Article

References (34)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47.
2. Crawford ED, Rosenblum M, Ziada AM, Lange PH. Overview: Hormone refractory prostate cancer. Urology 1999;54:1-7.
3. Israeli RS, Powell CT, Fair WR, Heston WDW. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 1993;53:227-30.
4. Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, Knudsen B, Bander NH. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 1997;57:3629-34.
5. Chang SS, Reuter VE, Heston WDW, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999;59:3192-8.
6. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial cells and serum of prostatic cancer patients. Anticancer Res 1987:7:927-36.
7. Maraj BH, Whelan P, Markham AF. Prostate-specific membrane antigen. BJU Int 1998;81:523-8.
8. White CA, Weaver RL, Grillo-Lopez AJ. Antibody-targeted immunotherapy for treatment of malignancy. Annu Rev Med 2001;52:125-45.
9. Mizushima S, Nagata S. pEF-BOS, a powerful mammalian expression vector. Nucleic Acids Res 1990;18:5322.
10. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual, 2nd Ed. Cold Spring Harbor, NY: Cold Spring Harbor Press, 1989.
11. Mantal N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50: 161-70.
12. Dawson-Sanders B, Trapp RG. Basic and Clinical Biostatistics. Norwalk, CT: Appleton Lange, 1990, 192-200.
13. Belldegrun A, Bander NH, Lerner SP, Wood DP, Pantuck AJ. New approaches and targets for advanced prostate cancer. J Urol 2001;166: 1316-21.
14. Small EJ, Reese DM. New treatment strategies in advanced prostate cancer. Radiol Clin North Am 2000;38:203-11.
15. Simons JW, Mikhak B. Ex vivo gene therapy using cytokine-transduced tumor vaccines: Molecular and clinical pharmacology. Semin Oncol 1998;25:661-76.
16. Hwang LC, Fein S, Levitsky H, Nelson WG. Prostate cancer vaccines: Current status. Semin Oncol 1999;26:192-201.
17. Harris DT, Matyas GR, Gomella LG, Talor E, Winship MD, Spitler LE, Mastroangelo MJ. Immunologic approaches to the treatment of prostate cancer. Semin Oncol 1999;26:439-47.
18. Pantuck AJ, Zisman A, Henderson D, Wilson D, Schreiber A, Belldegrun A. New biologicals for prostate cancer prevention: Genes, vaccines, and immune-based interventions. Urology 2001;57(Suppl 1):95-9.
19. Sanda MG, Restifo NP, Walsh JC, Kawakami Y, Nelson WG, Pardoll DM, Simons JW. Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst 1995;87: 280-5.
20. Blades RA, Keating PJ, McWilliam LJ, George NJ, Stern PL. Loss of class I expression in prostate cancer: Implications for immunotherapy. Urology 1995;46:681-7.
21. Bander NH, Yao D, Liu H, Chen YT, Steiner M, Zuccaro W, Moy P. MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma. Prostate 1997;33:233-9.
22. Lapidus RG, Tiffany CW, Issacs JT, Slusher BS. Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells. Prostate 2000;45:350-4.
23. Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 1998;52:627-40.
24. Wright GL Jr, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, Trayer J, Konchuba A, Schellhammer PF, Moriarity R. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996;48:326-34.
25. Mincheff M, Tchakarov S, Zoubak S, Loukinov D, Botev C, Altankova I, Georgiev G, Petov S, Meryman HT. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: A phase I/II clinical trial. Eur Urol 2000;38:208-17.
26. Kim JJ, Yang JS, Dang K, Manson KH, Weiner DB. Engineering enhancement of immune responses to DNA-based vaccines in a prostate cancer model in rhesus macaques through the use of cytokine gene adjuvants. Clin Cancer Res 2001;7:882s-9s.
27. Glennie MJ, Johnson PW. Clinical trials of antibody therapy. Immunol Today 2000;21:403-10.
28. Liu H, Rajasekaran AK, Moy P, Xia Y, Kim S, Navarro V, Rahmati R, Bander NH. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res 1998;58:4055-60.
29. Holmes EH. PSMA specific antibodies and their diagnostic and therapeutic use. Expert Opin Investig Drugs 2001;10:511-9.
30. Chang SS, Reuter VE, Heston WD, Gaudin PB. Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma. Urology 2001;57:1179-83.
31. McDevitt MR, Ma D, Lai LT, Simon J, Borchardt P, Frank RK, Wu K, Pellegrini V, Curcio MJ, Miederer M, Bander NH, Scheinberg DA. Tumor therapy with targeted atomic nanogenerators. Science 2001; 294:1537-40.
32. Sundarapandiyan K, Deo YM, Hudson D, Braziano RF. Bispecific antibody-mediated destruction of prostate cells. Proc Am Assoc Cancer Res 2000;41:289.
33. Kuratsukuri K, Wang CY, Sone T, Nishisaka N, Jones RF, Haas GP. Induction of antibodies against prostate-specific membrane antigen (PSMA) by vaccination with a PSMA DNA vector. Eur Urol 2002; 42:67-73.
34. Wang CY, Kuratsukuri K, Kinoshita Y, Nishisaka N, Jones RF, Kaumaya PT, Haas GP. Cytotoxic monoclonal antibodies against prostate-specific membrane antigen. Proc Am Assoc Cancer Res 2002;43:91.